![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
在COVID-19中适当使用托西利祖马布:早期使用是有益的
Lütfiye Nilsun Altunal1, Mehtap Aydın1, Ayşe Serra Özel1
1Department of Infectious Diseases, Health Sciences University Ümraniye Training and Research Hospital, İstanbul, Turkey.
Infectious diseases & clinical microbiology
|April 18, 2024
概括
托西利祖马布 (TCZ) 通过降低死亡率有效治疗严重的COVID-19. 早期的TCZ管理,特别是在重症监护室 (ICU) 入院之前,并且具有高C反应蛋白 (CRP) 水平,对于预防死亡至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 关键护理医学 关键护理医学
背景情况:
- 严重的COVID-19可以引发细胞因子风暴,导致高死亡率.
- 托西利祖马布 (TCZ) 是一种互乐金-6抑制剂,它有望缓解这种反应.
- 在COVID-19中使用TCZ的最佳时间和患者选择需要进一步阐明.
研究的目的:
- 在严重至严重的COVID-19肺炎病例中描述TCZ的适当使用.
- 为了确定影响TCZ治疗的患者在早期大流行期间死亡率的因素.
主要方法:
- 对67名PCR阳性COVID-19患者进行了回顾性观察性研究,这些患者接受TCZ治疗.
- 数据从2020年4月01日到2020年6月30日,在土耳其的一个中心收集.
- 后勤回归分析以确定28天死亡率的预测因素.
主要成果:
- 在住院患者中,28天死亡率为51%.
- 死亡的预测因素包括并发症的数量,TCZ前高C反应蛋白 (CRP) 水平,ICU中的TCZ启动,以及缺乏额外的TCZ剂量.
- 男性的性别和61岁的平均年龄是观察到的特征.
结论:
- 同病症,高CRP,ICU启动的TCZ和单剂量TCZ是死亡的重要风险因素.
- 对疑似细胞因子风暴的早期TCZ启动是预防死亡的适当措施.
- 对TCZ剂量策略和时间进行进一步研究是有必要的.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
01:26COPD: Management Using Bronchodilators and Corticosteroids
198
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
198
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:28Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324